Stock listing

Oryzon Genomics Sa

Selected listing: A2ACV2 · LSX · EUR · DE

Oryzon Genomics Sa (LS Exchange: A2ACV2), Health Technology. Latest release Sep 29, 2026: ORYZON receives European Medicines Agency approval to initiate…

A2ACV2:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A2ACV2
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: LS Exchange
Currency: EUR

Latest news from Oryzon Genomics Sa

ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid Syndrome

September 29, 2026

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

September 28, 2026

ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib

August 31, 2026

Oryzon Genomics S A : reports financial results and corporate update for half year ended June 30th, 2026

July 27, 2026

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

July 8, 2026

All Oryzon Genomics Sa news →

Research Oryzon Genomics Sa

Oryzon Genomics Sa company profile

View the public company page for Oryzon Genomics Sa on 6ix.

Oryzon Genomics Sa news

Read company news and market updates connected to Oryzon Genomics Sa.

Oryzon Genomics Sa investor events

Find investor webinars, events, and replay context for Oryzon Genomics Sa.